Catalyst Pharmaceuticals (Nasdaq:CPRX) - Stock Price, News & Analysis

CPRX Stock Overview

A commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.

About the company

CPRX fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 68.8% below our estimate of its fair value

Earnings are forecast to grow 19.97% per year

Analysts in good agreement that stock price will rise by 55.4%

Risk Analysis

Shareholders have been diluted in the past year

Profit margins (15.8%) are lower than last year (38.8%)

Catalyst Pharmaceuticals, Inc. Competitors

MannKind

NasdaqGM:MNKD

US$1.6b

Protagonist Therapeutics

NasdaqGM:PTGX

US$2.1b

Kiniksa Pharmaceuticals International

NasdaqGS:KNSA

US$1.5b

Dynavax Technologies

NasdaqGS:DVAX

US$1.4b

Price History & Performance

Summary of all time highs, changes and price drops for Catalyst Pharmaceuticals
Historical stock prices
Current Share Price	US$17.56
52 Week High	US$17.94
52 Week Low	US$11.55
Beta	0.70
11 Month Change	12.64%
3 Month Change	16.14%
1 Year Change	30.95%
33 Year Change	212.46%
5 Year Change	258.37%
Change since IPO	187.87%

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jul 24

Catalyst Pharmaceuticals: New Products In Proving Phase

Jul 06

Recent updates

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jul 24

Catalyst Pharmaceuticals: New Products In Proving Phase

Jul 06

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11

Shareholder Returns

	CPRX	US Biotechs	US Market
7D	3.4%	-0.5%	-1.6%
1Y	30.9%	14.9%	19.8%

Return vs Industry: CPRX exceeded the US Biotechs industry which returned 14.9% over the past year.

Return vs Market: CPRX exceeded the US Market which returned 19.8% over the past year.

Price Volatility

Is CPRX's price volatile compared to industry and market?
CPRX volatility
CPRX Average Weekly Movement	4.6%
Biotechs Industry Average Movement	10.6%
Market Average Movement	5.9%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	2.9%

Stable Share Price: CPRX has not had significant price volatility in the past 3 months.

Volatility Over Time: CPRX's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2002	167	Rich Daly	www.catalystpharma.com

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type.

Catalyst Pharmaceuticals, Inc. Fundamentals Summary

How do Catalyst Pharmaceuticals's earnings and revenue compare to its market cap?
CPRX fundamental statistics
Market cap	US$2.01b
Earnings (TTM)	US$65.12m
Revenue (TTM)	US$411.35m

31.9x

P/E Ratio

5.0x

P/S Ratio

Is CPRX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CPRX income statement (TTM)
Revenue	US$411.35m
Cost of Revenue	US$146.71m
Gross Profit	US$264.64m
Other Expenses	US$199.52m
Earnings	US$65.12m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 07, 2024

Earnings per share (EPS)	0.55
Gross Margin	64.33%
Net Profit Margin	15.83%
Debt/Equity Ratio	0%

How did CPRX perform over the long term?

See historical performance and comparison

CPRX Stock Overview

Rewards

Risk Analysis

Catalyst Pharmaceuticals, Inc. Competitors

NasdaqGM:MNKD

US$1.6b

NasdaqGM:PTGX

US$2.1b

NasdaqGS:KNSA

US$1.5b

NasdaqGS:DVAX

US$1.4b

Price History & Performance

Recent News & Updates

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Catalyst Pharmaceuticals: New Products In Proving Phase

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE

Consensus EPS estimates fall by 17%

Recent updates

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Catalyst Pharmaceuticals: New Products In Proving Phase

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Insider recently sold US$411k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Co-Founder exercised options to buy US$4.3m worth of stock.

Investor sentiment improves as stock rises 15%

Price target increased by 13% to US$26.20

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold US$570k worth of stock

COO & Chief Scientific Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Consensus EPS estimates fall by 23%

Investor sentiment deteriorates as stock falls 28%

COO & Chief Scientific Officer exercised options to buy US$1.3m worth of stock.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023

Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per Day

Independent Director exercised options and sold US$481k worth of stock

Insider exercised options and sold US$747k worth of stock

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS exceeds analyst expectations

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Catalyst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Investor sentiment deteriorates as stock falls 30%

Investor sentiment improved over the past week